Journal
NPJ BREAST CANCER
Volume 6, Issue 1, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41523-020-0153-3
Keywords
-
Categories
Funding
- Office of the Assistant Secretary of Defense for Health Affairs through the FY15 Breast Cancer Research Program [W81XWH-16-1-0385]
Ask authors/readers for more resources
Human epidermal growth factor receptor 2-positive (HER2(+)) breast cancer accounts for 25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2(+) breast cancer. In this narrative review, we summarize advances in the understanding of immune system interactions, examine clinical developments, and suggest rationales for future investigation of immunotherapies for HER2(+) breast cancer. Complex interactions have been found between different branches of the immune system, HER2(+) breast cancer, and targeted treatments (approved and under investigation). A new wave of immunotherapies, such as novel HER2-directed mAbs, antibody drug conjugates, vaccines, and adoptive T-cell therapies, are being studied in a broad population of patients with HER2-expressing tumors. The development of immunotherapies for HER2(+) breast cancer represents an evolving field that should take into account interactions between different components of the immune system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available